LH

TentativeAI MemoPost-earnings T+3

Labcorp

As of 2026-08-04/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-04 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 beat and raised FY2026 outlook • 2026-07-30

Base target: $338 / p=50% prob

Biggest risk

The initial post-earnings gain was followed by a 2.01% decline on July 31 and a 0.58% decline on August 3, suggesting some digestion. ACA-related volume pressure, potential PAMA reimbursement effects, execution risk, and recent insider sales remain offsets.

Invalidation

Break below $275 or thesis failure.

What would change my mind?

The Q2 beat, margin expansion, raised FY2026 guidance, specialty-testing traction, and biopharma backlog support a constructive earnings-revision thesis.

Research note

Recommendation

—

Confidence

high

As of

2026-08-04

Base target

$338

p=50%

Bull target

$360

p=30%

Bear target

$275

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print analyst target revisions
NASHnext Medicare coverage checkpoint
The Q2 beat, margin expansion, raised FY2026 guidance, specialty-testing traction, and biopharma backlog support a constructive earnings-revision thesis.

BearKey bullets

Analyst consensus breadth, options positioning, short interest, and social coverage are unavailable in the packet.
Higher specialty-testing, consumer, acquisition, and biopharma growth assumptions must convert into sustained volume and margin gains.
Management expects an approximately 30-basis-point 2026 Diagnostics volume headwind from ACA-related changes, with reimbursement policy risk still unresolved.

WatchKey bullets

Q2 beat and raised FY2026 outlook

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $338 (p=50%)

Target spread vs base: +6% / -19%

Scenario probabilities

Bull Target: $360 (p=30%)Base Target: $338 (p=50%)Bear Target: $275 (p=20%)

Commentary

News tone is strongly positive after the earnings beat and guidance increase. LH rose 2.73% on July 30, then gave back part of the move over the following sessions; subsequent analyst target increases were constructive. [Price history](https://stockanalysis.com/stocks/lh/history/) Social, options, short-interest, and employee-sentiment data are unavailable, so confidence should remain below a full-conviction bullish rating.

As of 2026-08-04 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

The Q2 beat, margin expansion, raised FY2026 guidance, specialty-testing traction, and biopharma backlog support a constructive earnings-revision thesis.

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print analyst target revisions
NASHnext Medicare coverage checkpoint

Scenarios

Bull Target (Scenario probability)

$360 / p=30% prob

Base Target (Scenario probability)

$338 / p=50% prob

Bear Target (Scenario probability)

$275 / p=20% prob

Analysis 2026-08-04 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-30
Q2 beat and raised FY2026 outlook
Q2 revenue was $3.73 billion, adjusted EPS was $4.99, and Labcorp raised revenue-growth midpoint guidance by 30 basis points and adjusted EPS midpoint guidance by $0.30; the remaining repurchase authorization rose to $1.4 billion. [#SEC-8K-2026-07-30] [SEC 8-K](https://www.sec.gov/Archives/edgar/data/920148/000092014826000162/form8-kexhibit9912q26.htm)
Prob 85.00% • Move 4.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

Post-print analyst target revisions
2026-08-08
Several analysts raised price targets after the print, including JPMorgan to $360 from $330 and Piper Sandler to $309 from $300, while maintaining their respective ratings. [Analyst revision coverage](https://www.tipranks.com/news/the-fly/labcorp-price-target-raised-to-360-from-330-at-jpmorgan-thefly-news)
Prob 70% • Move 4% • Priced-in 45%

Long-term Catalysts

Months to a year

NASHnext Medicare coverage checkpoint
2027-08-04
Stored earnings-call context says Labcorp's NASHnext blood-based liver-disease test is scheduled to receive Medicare coverage beginning in mid-August, creating a dated reimbursement and commercialization checkpoint alongside continued specialty-testing rollout. [#PR-EARNINGS-2026-07-31]
Prob 60% • Move 8% • Priced-in 35%

Risks

Analyst consensus breadth, options positioning, short interest, and social coverage are unavailable in the packet.
Higher specialty-testing, consumer, acquisition, and biopharma growth assumptions must convert into sustained volume and margin gains.
Management expects an approximately 30-basis-point 2026 Diagnostics volume headwind from ACA-related changes, with reimbursement policy risk still unresolved.
Recent open-market sales by the CEO and chief legal officer are a secondary sentiment risk, not evidence of operating deterioration. [#SEC-FORM4-2026-05-13] [#SEC-FORM4-2026-06-10]

Peers

Symbol	Summary
DGX	Closest laboratory-services peer. Packet context reports Q2 revenue growth of 10.2%, adjusted EPS growth of 19.1%, and raised 2026 guidance, providing a direct operating benchmark, though valuation and margin comparisons remain incomplete.
ABT	Broader but relevant diagnostics comparator: Abbott reported Q2 2026 sales of $12.6 billion, 13.3% comparable growth in Cancer Diagnostics, 7.5% U.S. Core Laboratory growth, and raised adjusted EPS guidance. Its diversified medical-device and pharmaceutical businesses reduce comparability. [Abbott Q2 2026 earnings](https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/abbotts-Q2-2026-earnings-call)

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-04

Loading AI feed…

Symbol

Summary

DGX

Closest laboratory-services peer. Packet context reports Q2 revenue growth of 10.2%, adjusted EPS growth of 19.1%, and raised 2026 guidance, providing a direct operating benchmark, though valuation and margin comparisons remain incomplete.

ABT

Broader but relevant diagnostics comparator: Abbott reported Q2 2026 sales of $12.6 billion, 13.3% comparable growth in Cancer Diagnostics, 7.5% U.S. Core Laboratory growth, and raised adjusted EPS guidance. Its diversified medical-device and pharmaceutical businesses reduce comparability. [Abbott Q2 2026 earnings](https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/abbotts-Q2-2026-earnings-call)